



# Marksans Pharma Ltd

10<sup>th</sup> April, 2017

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400051

Scrip Code: **MARKSANS**

To,  
**BSE Limited**  
P. J. Towers  
Dalal Street  
Mumbai – 400 001

Scrip Code: **524404**

Dear Sirs,

We wish to inform you that the United States Food and Drug Administration (US FDA) inspected our manufacturing facility located at L-82 & L-83, Verna Industrial Estate, Verna, Goa – 403722 from 3<sup>rd</sup> to 7<sup>th</sup> April, 2017.

At the end of the inspection, there were 4 (four) observations given under Form 483. The Company has already started addressing the same and is confident of satisfying the FDA within the stipulated time.

Further, on 7<sup>th</sup> April, 2017, US FDA has also granted final approval of the Abbreviated New Drug Application for Dutasteride Soft Gelatin Capsules 0.5 mg, which is therapeutically equivalent to the reference listed drug (RLD), Avodart® Capsules, 0.5 mg of GlaxoSmithKline. Dutasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. Marksans will launch the product immediately.

This is for your information and records.

Thanking you.

Yours faithfully,  
For **Marksans Pharma Limited**

Harshavardhan Panigrahi  
**Company Secretary & Manager – Legal**

CIN : L24110MH1992PLC066364

[www.marksanspharma.com](http://www.marksanspharma.com)

**Marksans Pharma Ltd.**

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,  
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011  
E-mail: [info@marksanspharma.com](mailto:info@marksanspharma.com)